Efficacy
Aggrenox®/Asasantin® was proven effective in two multicentre, placebo-controlled studies, the European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) and the European Stroke Prevention Study (ESPS 2).
ESPRIT was a blind, open-label study with 4,500 patients with an average follow-up of 3.5 years, where Aggrenox®/Asasantin® shows
Disclaimer
ESPRIT is an independent investigator initiated study
ESPRIT describes the use in a composite endpoint which is not part of the Aggrenox® (Asasantin®) label
The dose range of ASA in ESPRIT was 30-325mg/day; on average less than 75mg/day
83% of the patients received dipyridamole; 8% the fixed-dose combination ER-dipyridamole + ASA 200/25mg twice daily, marketed as Aggrenox® and Asasantin® retard
